drugset / Trial / NCT00767468
Sorafenib in Treating Patients With Locally Advanced or Metastatic Liver Cancer and Cirrhosis
Phase 1
Terminated
6 enrolled
UNC Lineberger Comprehensive Cancer Center
National Cancer Institute (NCI) · collab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
RATIONALE: Sorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. PURPOSE: This phase I trial is studying the side effects and best dose of sorafenib in treating patients with locally advanced or metastatic liver cancer and cirrhosis.
Timeline
- Start
- 2008-10
- Primary completion
- 2010-02
- Completion
- 2010-11
Outcome
Outcome not reported
Stopped (Business): “Funding unavailable”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Sorafenib | Small molecule | 400 mg | Oral |